<DOC>
	<DOC>NCT00197821</DOC>
	<brief_summary>To compare the relative immunogenicity and reactogenicity of the existing 23 valent plain pneumococcal vaccine and a 7 valent pneumococcal conjugate vaccine in healthy UK adults aged 50-80 years, and subsequent antibody persistence and response to boosting.</brief_summary>
	<brief_title>Evaluation of the Immunogenicity and Reactogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Written informed consent for participation in the study; ages between 50 and 80 years at recruitment Lack of adequate comprehension of the information sheet, consent form and study nurse's explanation of the study in order to give informed consent. Current participation in any other clinical trial Any vaccination in the previous month (except influenza vaccination which can be given at any time during the study) Prior pneumococcal conjugate vaccine (PNC) 23 valent pneumococcal vaccine(PPV) in last 5 years Severe general or local reaction to a previous dose of PNC or PPV Patients currently immunocompromised as listed in UK Handbook "Immunisation Against Infectious Disease" ed 1996 Patients who have received intravenous immunoglobulin in the previous month or who will require replacement intravenous immunoglobulin during the period of the study Patients in whom pneumococcal vaccination (PPV) is currently recommended as per the UK Handbook "Immunisation Against Infectious Disease" Deferral of vaccination if acute systemic illness or temperature &gt;38C on day of vaccination</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>